REVIEW ARTICLE

Targeted Drug Delivery: The Principles, Issues, and Prospects from Magic Bullet to Nanomedicine

S. Waghade, Sunita N. Vaidya, S. Agrawal, V. Satote, V. Gulghane, M. V. Muley, S. Kale

Department of Pharmaceutics, Datta Meghe College of Pharmacy Salad (H), Data Meghe Institute of Higher Education and Research (D.U.)/FDDD, Wardha, Maharashtra, India

Abstract

Using a targeted drug delivery system, a medicine's component is sent straight to the target. The body part (cells, organs, and subcellular layers of a particular group of cells) eliminates the non-specific toxicity of commonly administered medications, thereby depleting essential medications' effectiveness. The magic bullet concept was developed to achieve this goal, and for more than a century, it has inspired scientists to investigate and reflect. Nanometer-sized devices are referred to as cutting-edge nanomedicine for targeted drug delivery. Various polymers, colloidal (vesicular and multiarticulate), and cellular and subcellular structures for transport have been used and studied. This review discusses the significance and benefits of targeting, as well as its basic principles, methods, and logistics systems. It also focuses on recent developments, problems, and outlooks for the future.

Key words: Carriers, nanoparticles, nanosomic, polymers, target

INTRODUCTION

The processes, formulations, technologies, and techniques utilized to transfer pharmaceutical substances through the body to produce the intended therapeutic results are known as "drug delivery" (DD). To achieve therapeutic efficacy, it covers methods for giving drugs to humans and animals.[1] Current developments in DD systems (DDSs) have mostly focused on smart DD (smart DD), which attempts to optimize safety and efficacy by administering medication at a suitable time, dose, and location.[2] Over the past few years, novel DDSs (NDDSs) have received a lot of attention. Through targeted, regulated, and sustained distribution, these systems improve the therapeutic efficacy of both novel and old pharmaceuticals while addressing actual and reasonable drug demand.[1] DD is growing in the field of medicinal science. Out of the five DDS generations, the fourth one includes targeted delivery.[3] The several DDS generations are depicted in Figure 1. For the past few decades, the creation of sustained or controlled DDSs has aimed to decrease the frequency of dosages, control and/or maintain drug release, and/or boost pharmacological efficacy relative to traditional delivery methods. The use of bilayer tablets is one instance of an NDDS that changes conventional medication manufacturing and delivery techniques. Because two of the same medication or two distinct medications fixed in a single dose make up these combinations, one serves as a loading dose and the other as a maintenance dose. The combined drugs can be released sequentially or in a sustained and immediate manner.[4] Still, there are certain DDSs that require improvement. These consist of protein delivery, independent insulin delivery, targeted DDSs (TDDSs), and the delivery of drug formulations that are poorly soluble. Such adjustments to all versions of standard DD may signify advances in the offering. Another potential development can be created using DSs based on nanotechnology for targeted tumor delivery.[5] Nanoparticle (NP)-based DD allows for controlled drug release, giving pharmaceuticals enough time to reach their maximum therapeutic effect and respond

Address for correspondence:
Sunita N. Vaidya, Datta Meghe College of Pharmacy Salod (H), Datta Meghe Institute of Higher Education and Research (D.U.), Wardha - 442 002, Maharashtra, India. Phone: +91-9284591082.
E-mail: sunitavaidya06@gmail.com

Received: 01-11-2023
Revised: 18-12-2023
Accepted: 29-12-2023



Figure 1: Targeted drug delivery is required

to different stimuli such as pH, heat, light, or enzymes.[6] DDSs known as TDDSs integrate various scientific fields, such as the study of polymers, pharmacology, bioconjugate science, and molecular biology, to administer medication to a particular site as opposed to the body or organism as a whole. To administer medication to a particular site as opposed to the body or organism as a whole. TDD seeks to regulate and control the immunogenicity, biorecognition, specific adverse effects, and pharmacological kinetics and dynamics of the medicinal drug.[7] Reducing adverse effects while boosting therapeutic effectiveness is the ultimate goal. Unlike conventional or traditional DDSs, which depend on drug absorption across biological membranes, target-specific drug release from a dosage form is acquired by TDDSs.[8]

CONSIDERING THE MAGIC BULLET

The idea of getting medications to their sites of action is based on the "magic bullet" paradigm. Paul Ehrlich first proposed the idea of using "magic bullets" to target a virus selectively while sparing the host organism.[9] More than a century ago, this concept was very inspiring to analysts who focused on cancer treatment.[10] Ehrlich worked on his "magic bullet" concept in two phases: First, he screened for hazardous medications, and then he changed those drugs to make them less toxic and more targeted.[11] He had a clear vision of treating the bacteria on their own by employing compounds that were specifically affine to them with no side effects on the host. As a deadly action that was limited to the parasite inside the creature, this would eventually have the least negative effect on humans — thus the term "magic bullet." In Gradmann,[12] Ehrlich expected site-specific therapy to teach him how to employ those he targets because a shooter's magic bullets only hit targets. This fascinating theory inspired scientists to conduct more research for over a century, which resulted in the discovery of multiple tiny things that are today referred to as "nanomedicines."[13] Its success shows how well accepted this concept is, but putting the magic solution into practice still proves to be difficult. This is due to the challenges in identifying the most effective therapeutic target for a given disease state. The drug used to treat the sickness must deliver the medication in a stable state to specific sites without immunologic side effects or unusual interactions. NPs have the potential to be useful as DD vehicles and, in conjunction with targeting ligands, can fulfill numerous criteria for a miracle cure.[9] Ehrlich thought that medications should only come into contact with the molecules they are meant to target when they are taken straight to their designated locations in the body. The "magic bullet" notion is the name for this concept. However, medications have to go through complex pathways and interactions to reach their targets and might interact with many targets, which can result in side effects. Regretfully, no medication or DDS has ever been able to directly reach the biological target without the assistance of these pathway interactions. The medicine affects several targets at once, making it a "magic shotgun" slightly more than a "magic bullet." Still, we have. We still have quite a ways to go before we can achieve the magic bullet goal.[14]

TARGETED DD IS REQUIRED

TDD is superior than traditional DSS for the following four reasons: The inadequate pharmacodynamic, pharmacokinetic, medicinal, and pharmacotherapeutic aspects of medication performance with traditional delivery are illustrated in Figure 1.

Improved DD strategies should be employed to target a specific location with drugs to maximize therapeutic efficacy while minimizing toxicity from high dosages and a small therapeutic index.[15] Targeting is necessary to find solutions to these limitations and the inherent problems with conventional DDSs. Parenteral administration is a fairly intrusive operation; topical ointments and creams can only act locally; and drugs produced from proteins or peptides cannot be taken orally. Furthermore, if the medication is not administered to the site of action at a quantity and pace that maximizes therapeutic properties while minimizing side effects, the efficiency of drug-target interactions is compromised.[8] TDD has the potential to reduce drug levels, streamline medicine administration procedures, and enhance drug concentration in target compartments without adversely affecting other target compartments. In general, drug targeting leads to increased efficacy, reduced toxicity, improved patient compliance, increased localization specificity, controlled biodistribution, and modulated pharmacokinetics.[8,16]

FUNDAMENTAL IDEAS AND USES OF TARGETED DDSS

Delivering a high concentration of the medication to the intended site and a low absorption to the unwanted area is the basic principle of drug targeting. This theory serves to maximize the therapeutic effects of the medicine while minimizing its adverse effects because of relations between various goals, greater dosages, and non-target absorptions.[17] Directing minimizes drug interactions with bioenvironmental variables that impact DD to the body's targeted areas.[18] Coordinated drug use, the target's location, and the DD mechanism are all included in drug targeting. The target is the particular organ, cell, or pair

of cells that the medication will come into contact with and that require therapy for an acute or chronic illness. A specially designed molecule or system known as a "carrier" is required for the well-organized delivery of a loaded drug to a set of precise websites.[19] Ideally, a drug-targeting complex should be biocompatible, recyclable, immunogenic, chemically inert, and stable both *in vivo* and *in vitro*. It must also have minimal drug leakage during transportation, be reasonably easy to prepare, repeatable, affordable, and easy to remove from the body. In addition, it must provide an expected and controllable prototype of drug release.[16,20] Targeted drug products are supposed to be created while taking into account the unique characteristics of target tissues and the type of transport vehicles or transporters that deliver the medication to particular receptors to ensure the satisfaction of those ideal features. These important factors include the drug concentration, the location and distribution of the particulate matter, the molecular weight, the physicochemical characteristics, the presence of enzymes and electric fields, the physiological environment, the type and concentration of the excipients or polymers, and the surface form (shape, charge, dimensions, and density) of the carrier system.[16] For the actual targeting of desired cells or groups of cells, physicochemical parameters such as carrier mathematics, avidity, structure, and functioning should be controlled along with physical variables such as, for example, plasma flow for intravenous drug administration and tissue construction.[21] In addition, drainage, intratumoral transportation, tumor heterogeneity, and overexpression characteristics are crucial components of an efficient tumor-targeted therapy.[14] TDD can be used successfully in cutting-edge nanomedicine and therapeutics if its ideal characteristics are well-met and its formulation Everything is carefully thought out. TDD is useful in treating a range of infectious and chronic diseases, but because it increases the concentration and penetration of microphages at the infection site, it is most useful in the treatment of malicious tumors.[3] The potential applications of TDD include cancer therapy, adjuvant vaccines, ocular and cerebral delivery, DNA and nucleotide delivery, intracellular and systemic targeting, oral and dermal administration, enzyme antibodies, and radio imaging.

Results improved immunoresponse, enhanced drug assimilation and infiltration, enhanced drug retention or decreased washout, extended systemic circulation through improved bioavailability and medicine effect, and decreased toxicity are typical benefits from these applications. Prolonged systemic circulation.[20]

DIFFERENT TARGETED DDS TYPES

Passive and active targeting

Systemic circulation is the goal of passive targeting in DD. In this method, drug targeting happens as a product of the body's physiological reaction to the physicochemical properties of the medication or drug-carrier system. This is predicated on the drug(s) building up in areas that target the location of interest, like in the case of tissue from a tumor.[3] The use of NPs as carriers in passive targeting allows for the important accumulation of drugs at the target because they are designed to pass through blood vessels more readily at the disease site. The enhanced permeability and retention (EPR) effect, which causes slow lymphatic drainage, facilitates this process.[6] However, active targeting is a specific ligand receptor-type interaction that happens after extravasation and blood circulation.[15] It primarily depends on the physiological interface between the ligands on NPs and the target cells.

Proteins, carbohydrates, nucleic acids, peptides, and tiny compounds have all been used.[6,8]

According to the EPR effect, tumors have severely damaged vessel construction and inadequate lymphatic drainage. Small nanocarriers with these tumor characteristics are thought to be suitable for passive targeting of anticancer drugs because they have relatively smaller cross-sections than unusual blood-vessel gaps and are therefore more easily able to locate and reach tumors with precision.[22] Recent research, however, has shown that NP transport and accumulation into solid tumors are not caused by interendothelial gaps in tumors. According to one study, endothelial cells play an active role in up to 97% of NP transport into tumors.

These studies imply that the EPR effect in oncology patient clinical cases has not yet been established. On the other hand, it is anticipated that more active transport mechanisms, such as the EPR effect, will be better at absorbing targeted NPs from the circulatory system into the tumor microenvironment.[23] Even though the creation of NPs for targeting has many positive benefits, particularly in cancer chemotherapy, it is not noticeably superior to that of the original drug treatments. Due to the complicated characteristics connected to the nanodrug dimension as well as tumor pathology, there is inadequate and unfinished nanodrug penetration into tumor tissue.

Among the proven methods for encouraging tumor entry with nanodrugs are dimensional change, carrier charge inversion, surface modification, and remodeling the microscopic environment of tumor tissues. Application of tumor targeting is still in its early stages, and chemotherapy for cancer still faces many challenges. Therefore, DD and targeting structures with greater bioresponsiveness, fewer side effects, and improved therapeutic efficacy are needed.[24]

Targeting of the first, second, third, and fourth order

Three (or four) distinct levels of targeting can be used to further categorize drug targeting. The drug-carrier system's



Figure 2: Different classes of targeted drug delivery systems

distribution to the target site's capillary bed is constrained in first-order targeting. Second-order targeting is the selective administration of medications to particular cell types, like tumor cells. Drugs that target macromolecules like DNA and proteins are sometimes designated as having fourth-order targeting, which refers to specifically targeting intracellular sites.[15]

Targeting in reverse, dual, double, and conjunction

The reticuloendothelial system will become saturated with the inhibition of its resistance systems if the usual activity of the system is blocked by an empty colloidal carrier to reduce its passive drug uptake, a technique known as inverse targeting. Delivery of a molecule that acts as a carrier with its own medicinal activity is known as dual targeting, and it increases the (synergistic) remedial impact of the medicine.

Double targeting combines chronological and spatial methodologies, which are the delivery of information at predetermined times and placing it in specific locations. Targeting directly at a target that has polymer compounds, carriers, and locating devices with cellular specificity is known as integration targeting.[3,20]

Targeting with the physical, chemical, as well as biological agents

Systems that place agents in target areas based on their dimension, composition, or other individuality rather than those that are particularly aimed at a biological receptor are known as physical targeting systems. Chemical targeting entails the localization of substances through the use of prodrugs designed for a particular site [Figure 2]. Enzymatic or else chemical processes that result in the targeting of the carrier or controlled dispersal or action of the agent can also be used to direct agents to specific areas. Through the application of antibodies (Abs), proteins, peptides, or other types of biomolecules that contain a precise affinity for the receptors, locations, or other biological targets, localized agents can target regions using biological targeting. Using cells, tissues, or other particular promoters in vector systems, the expression of genes can also be restricted to specific regions of interest.[25]

Local as well as systemic targeting

The main objective of drugs is delivered to the local site for the treatment of local pathologies using locally targeted systems, which are noninvasive targeting techniques. Systemic targeting allows for the invasive delivery of such therapeutic systems, such as intravenous delivery of nanotechnological systems. These systems deliver the medication through systemic circulation after it has been dispersed throughout the body. Drug side effects in a specific tissue are the primary cause of such systems' drawbacks.[26]

Disease and location-based targeting

TDD is a targeted delivery method that targets delivery to certain cells, systems, and organelles that are using location-based strategies. Location-based targeting includes but is not limited to, intracellular, respiratory tract, brain, and gastrointestinal tract (GIT) targeting. Drug-loaded nanocarriers, proteins, Abs, and other intracellular delivery mechanisms of pharmaceuticals ensure that the remedial effect is specifically delivered to the center or particular organelles. Antiviral, antifungal, and antibacterial agents

are absorbed from extremely particular areas of the GIT in a method known as floating DD. For the purpose of targeting the abdomen, duodenum, small intestinal tract, lymph nodes, and colon, various local oral controlled-release structures were created. While disease-based TDDS is a site-specific treatment, polymer-based DDSs like dopamine and liposome conjugates demonstrate successful targeting of the brain with lower degradation during flow. Using nano-DDSs to treat infections might be a useful substitute for antibiotic therapy. A novel idea is to create nanovaccines with improved cellular responses and advanced targeting. Specific and specialized methods are being developed to target some significant pathogens that persist inside the cell. These include the antimicrobial functionalization of NPs.[2,17,19,26]

SYSTEMS FOR VEHICLES AND CARRIERS FOR TARGETED DD

Drug carriers are another name for drug vectors; these are the most crucial constituents needed for the successful delivery of a loaded drug to its intended target. They move, hold, and deliver the medication inside or near the target. They can carry out these particular tasks thanks to a small structural modification. The current state of DD technology has been improved by taking into account a number of variables, including timing for ideal DD, pharmacokinetic processes, and bioavailability.[17,27] Different carrier systems are needed for TDDSs, depending on the kind of targeting mechanism. TDD carriers and vehicles are specifically designed vectors that can bind with the aid of a spacer moiety or encapsulate the drug to keep it inside or on them intended for polymeric vehicles such as NP-based carriers, liposomes, micelles, and lipoprotein-based carriers, these DD vehicles are employed.[28,29] Hazardous, secure, nonimmunogenic, biodegradable, biocompatible, easily detached from the human body, and unrecognized by the host's defense mechanism are the ideal properties for TDD carriers. They must also successfully deliver the medicine to the intended site, pass through barriers, and cancer vasculatures as essential, be of satisfactory dimensions and form (for nanocarriers), have the best discharge characteristics at the target location, and have no or very little drug loss before that target site. Transporters are supposed to also have pre-procedures that are reasonably easy to reproduce, affordable, and efficient.[28,29] Managing the distribution in the body profile of the drug and vehicle material will enable the DDS to have the best possible target selectivity and specificity. The biodistribution profile is calculated based on the physical, chemical, and biological characteristics of both parties.[30] Similarly, polymer biodegradation and drug release are crucial elements in creating an effective nanoparticulate system. In conclusion, the release process depends on the matrix materials' solubility, diffusion, and biodegradation.[31]

Frequently used vehicles for targeted DD

Drug carriers come in a variety of forms, including colloidals, polymers, monoclonal antibody Abs, NPs, and cells. The type of carrier that will be used depends on the drug, the intended target, and the stage of the illness. As targeting moieties, carriers are used with ab, proteins, lipoproteins, hormones, molecules that are charged, and polysaccharides.[16]

Systems for colloidal carrier

Colloidal DDSs are vesicular dosage forms or nanoscaled agents that target vesicles of particulate matter. Liposomes, niosomes, nanospheres, numerous emulsions, and ceramics are some of them.

These kinds of drug vectors have the capacity to change the distribution profile while transporting and retaining the active drug while eluting or delivering it inside or close to the target. They are frequently categorized as microparticulate and vesicular systems.[32]

Systems for vesicular carrier

The name "niosome" comes from the fact that the medication in these nanometric NDDSs is contained in vesicles made of a bilayer of unionic surface active agents. They are promising DDSs because they are nonionic, less noxious, and only affect target cells, increasing the drug's therapeutic index.[33-41] The physicochemical characteristics of niosomes and liposomes are comparable, with a few variations depending on the bilayer composition and processing techniques. While phospholipids make up the majority of liposomes, surfactants make up the majority of niosomes. In contrast to liposomes, which require special preparation or storage conditions, niosomes have excellent stability. This may lower the price of production.[42] However, liposomes and niosomes are not ideal for transdermal delivery due to their poor skin permeation, vesicle breaking, drug leakage, aggregation, and fusion. With the help of recently developed carrier systems called transferosomes, it is now possible to successfully deliver both low- and high-molecular-weight medications through the transdermal route.[43] Transferosomes are ultradeformable (ultraflexible) fat supramolecular gathers that have been specially designed to be able to penetrate mammalian skin unharmed. Incorporating edge-activator surfactants such as sodium cholate, Span eighty, and Tween eighty, they are made up of an inner water-soluble compartment and an outer lipid bilayer. By disorganizing the stratum corneum's highly organized intercellular lipids, they serve as penetration enhancers, allowing drugs to more easily penetrate and cross the corneum layer.[44] They serve as transporters for proteins and peptides such as insulin, albumin from cattle, and vaccines in therapeutic settings.

They enhance location specificity, enhance overall drug safety, and reduce drug doses for treating skin conditions.

They are used for efficient delivery of anti-inflammatory medications similar to ibuprofen as well as diclofenac due to their excellent permeation and flexibility.[43] Other vesicular carriers used to deliver medications include ethosomes. They penetrate biological membranes, primarily the skin, only slightly, but they penetrate the skin more than liposomes do. They are primarily used for transdermal DD and contain phosphate-lipid spirits (ethanol and isopropyl spirits) and water. Ethosomes are applicable to replace liposomes in favor of cutaneous delivery of drugs that are both hydrophilic and impermeable, primarily in favor of the transdermal route of DD.[44]

SYSTEMS FOR MICROPARTICULATES

DDSs on the micrometer and millimeter scale are referred to as microparticles. This microencapsulation technology enables the stabilization of delicate drug substances, the removal of non-compatibilities, and the masking of unpleasant tastes. As a result, microparticulatesare crucial DDSs, aiming to raise the bioavailability of traditional medications while lowering toxiceffects. Microparticles, NPs, and magnetic microspheres are all included in microparticulate systems.[45]

TDDS POLYMERIC CARRIERS

The foundation of pharmaceutical DDSs is polymers. Due to their special qualities that no other material has been able to match, they have been used extensively in DD. With adequate consideration of both surface and bulk properties, several NDDSs have been developed as a result of advancements in polymers, making medical treatment more effective, efficient, and secure.

In advanced DDSs, polymers are crucial because they help with delivery, act as excipients, and enable controlled, targeted drug release.[46] Controlled drug release is made possible by micro- and nanospheres made of a biodegradable polymer at the desired locations. Polymeric nanocarriers have demonstrated promising drug kinetics at both the whole-body and cellular levels, such as poly(D,L-lactide-co-glycolide).[47] In general, polymer-based nanocarriers for medicines may significantly boost the solubility of hydrophobic drugs, decrease their cytotoxicity toward healthy tissue, prolong the time that drugs circulate in the blood, promote the entry of NPs, and increase utilization efficiency. The use of artificial polymers, such as polymers, polyamides, and polypeptides, has received more attention in the field of DD than organic polymers such as chitosan and dextran, which have also been thoroughly studied in recent decades.[48] Micelles, nanomicelles, and dendrimers are examples of amphiphilic polymers that have undergone extensive research to be used as polymeric carriers in DD. Amphiphilic polymers can be used to create a variety of nanostructures, including spherical micelles, which are cylinder micelles, and vesicles, by manipulating the hydrophilic-hydrophobic balance. The most prevalent and reliable morphological forms of amphiphiles within water are polymeric micelles and vesicles. Hydrophilic drugs are contained within the hydrophobic core of polymeric micelles, which are nanostructures with a hydrophilic shell. In the meantime, drugs that are hydrophilic can be enclosed inside the aqueous interior of polymeric nanovesicles, integrating the molecules that are hydrophobic within the membrane. These nanovesicles have bilayer structures that surround a water-based interior core, separating the core from the external medium. As a result, water-friendly as well as hydrophobic medicines, such as anticancer medications, genes, and proteins, can be delivered by polymeric vesicles.[48] Drug molecules are physically entrapped in the hydrophobic core of polymeric micelles, avoiding the need for over-encapsulation functional groups as opposed to the hydrophilic external surface. Chemically coupling amphiphilic polymers to the micelles can increase loading and delay the release of the drug. A lipophilic drug's therapeutic window may be expanded by the hydrophobic core's enhanced transport of molecules with little or no aqueous solubility [Table 1].

As a result, intravenously given hydrophobic drugs are less likely to cause embolisms. Micelles also have a lower likelihood of quick drug clearance and a longer *in vivo* circulation time, which promotes drug buildup in tumor cells. These features make micelles made from polymers a significant new generation of nanomedicine with cutting-edge therapeutic and diagnostic clinical applications.[49,50] The other categories of polymeric carriers for drug targeting are dendrimers. They are well-articulated, multibranched globular macromolecules that are monodispersed. Dendrimers are made up of three main components, each of which has a specific function: The center of gravity, interior branching units, and functional groups on the exterior surfaces [Table 2]. Electrostatic communication and hydrophobic fragmentation are the two processes that trap polar and apolar drugs into dendrimers, respectively. The molecules of drugs may either be attached covalently to the outside groups or non-covalently bonded to the interior cavity of dendrimers through physical interaction. Examples of molecules that can be connected through electrostatic interaction include nucleic acids and gene plasmids. For DD, the covalent linkage provides a more reliable formulation. The type of linkage determines how the drug will be released.[49] Particle dimensions, form, surface, flexibility/rigidity, construction, and elemental composition are crucial nanoscale design factors that must be carefully taken into account for a dendrimer DDS to be successful.[51]

FRAGMENTS AND MONOCLONAL ANTIBODIES

Attention is being paid to monoclonal antibodies (mAbs) as medicines in the treatment of numerous chronic illnesses such as tumors and infections. To target tumors and increase their cytotoxic effects, they may be linked with chemotherapy

Table 1: Variations in vesicular carrier

Nanosomes	Main constituent	Applications	Specific property
Niosomes	Cholesterol, unionic surfactants	Carrier of amphiphiic drugs	No need of special storage
Liposomes	Phospholipids dispersed in water solutions	Used in targeted oral, topical DD	Needs special storage
Transfeosomes	Surfactants, dye, alcohol	Used for transdermal DD	Deformable and flexible vesicles
Ethosomes	Dye, phospholipid, cholesterol	Controlled transdermal DD	Novel and soft vesicles

DD: Drug delivery

Table 2: Structural components of Dendrimers

Structural components	Description
Core	The center of the dendrimer can be small molecule, nanoparticle
Void spaces	These are empty spaces between the core and interior branching
Interior branching	Multibranched globular unit with interior functional group
Exterior groups	Outer hydrophobic or lipophobic surface groups that is over the dendrimer and drug complex
Dendrimer-drug linkage	Non-covalent or covalent bond between dendrimer and drug

drugs, radioactive substances, bacterial toxin cytokines, and enzymes.

Human monoclonal antibodies are being developed today as antitumor medications. Adalimumab, for instance, was the first human mAb to be formally authorized for clinical use.[3]

RECENT DEVELOPMENTS, ISSUES, AND FUTURE PERSPECTIVES

Transporter systems and vehicles for DDSs, microsponges, solid-lipid NPs, and lipid carriers with nanostructured structures have all recently been used and further investigated. Microsponges are synthetic, biocompatible, inert plastics that can hold as much medication as their own weight. They are able to supply controlled distribution and shield the medication from the outside world. Several areas of nanomedicine, including drug and gene delivery, imaging, and diagnostics, have incorporated nanotechnology.

By covalently attaching via an antibody to a drug that targets potent drugs in specific places and employing the specificity of mAbs, ab-drug combines and immunoconjugates are being studied as alternatives to recombinant Abs, preventing non-targeted organ toxicity. Other developments are being looked into for regional and systemic targeting, including micro- and emulsion nanocapsules, smart pills, cyclodextrins, microspheres, nanotubes, nanoshells, quantum dot hydrogels, metallic and magnetic NPs, and synthetic and natural polymeric NPs.[2,52] Although recent developments have shown promise, there are also difficulties in applying them. Some of the major difficulties are outlined in the sections that follow.

ISSUES PARTICULAR TO RECEPTORS, LIGANDS, AND CARRIERS

The challenges unique to receptors include difficulties with receptor identification, variable expression characteristics, accessibility of receptors in terms of reachability and availability, and receptor shedding. The proper selection of a ligand, creating conjugation strategies that target ligands with drugs or carriers, and characterizing the release of drugs There are challenges specific to ligands (choosing a linker). The selection of carriers as well as their physicochemical and pharmacokinetic characterization is included in carrier-based challenges.[53]

MISCONCEPTIONS

TDD has some unsettling facts that are misunderstood and overlooked. First, targeting implies a random distribution rather than precision. Second, the idea of receptor excessive expression and targeted delivery has not yet been fully correlated. Third, the EPR effect results in improved delivery, though it is less precise than with targeted delivery. Fourth, drug release may occur before the intended site, and removing the tissue from the tumor does not always imply improved delivery.[5]

INTRICATE MANUFACTURING PROCEDURES

For the formulation of targeted drugs, extra processes in chemical synthesis and purification are required. Additional difficulties include more quality assurance and regulatory requirements, higher costs, and extended deadlines.

For nanocarriers, the design challenges of flexibility, sensitivity, biological compatibility, and poisoning are all related.[6,54]

HETEROGENEITY IN TUMORS

The extreme heterogeneity between and within tumors adds more complexity. In addition, there is stroma that is linked to tumors and metastases, such as fibroblasts and tumor-associated macrophages.[54]

ALMOST UNPREDICTABLE REAL-WORLD RESULTS

On how effectively drug-targeting strategies will work in practice, there is still a lot of disagreement. The effectiveness of these approaches is hardly predictable due to the lack of clinically applicable models that encompass specific targets, as well as the choice of focuses on with both temporal and spatial conveying that are close to interventional requirements.[55]

CLINICAL TRANSLATION BARRIERS

The practical application of nanomedicines into medical practice has been significantly hampered by untested low-than-expected NP accumulation within tumors with active killing processes, the EPR effect in human oncology clinical trials, and variables that need to be considered, adjusted, and tracked throughout the production and distribution of nanomedicines.[23] Particles size, charge on the surface, surface modification, and hydrophobicity are some of the physical factors that affect NP-based targeting.[63] The understanding of NP toxicity is still limited, and there are still many issues with selective binding and precise administration that need to be resolved. A new, more successful paradigm of drugs and research may result from taking into account these issues now and with future NP advancements.[56] Future perspectives on addressing these issues and getting the most out of targeted delivery are expanding and fascinating. In the sections that follow, a few are briefly mentioned.[62]

CLINICAL EXTRAPOLATION ADVANCES

The skill of overflowing clinical projections of TDDSs is still lacking.[61] This can only be accomplished using sophisticated carrier preparation techniques, reproducible methods, and thorough and comprehensive preclinical testing.[53]

DELIVERY TO SPECIFIC CELLS

The development of various NDDSs for cell-specific delivery as well as the identification of newer therapeutic targets all point to a bright future for receptor-targeted delivery.[53]

THERANOSTIC TECHNIQUE

Diagnostics and targeted therapy will be integrated into one, centrally located system of care in the future of nanomedicine.[64] With the help of this innovative theranostic approach, it may be possible to treat cancer and other long-term illnesses in a way that is highly selective, efficient, and relatively gentle. This could lead to personalized chemotherapy and better patient outcomes.[10]

STANDARDIZATION, ADVANCED MODELS, AND GOOD LABORATORY PRACTICES

As our understanding of the various processes that take place after administration has improved, targeting strategy development should also undergo ongoing evaluation.[16] The rate of clinical translation will increase as more advanced and accurate preclinical animal models are created, good laboratory practices and standardization guidelines are adopted, tumor biology is better understood, and real biomarkers are found.[54,60]

ENGINEERING PRECISION NPS FOR PRECISION MEDICINE

Precision medicine, which optimizes drug design and dosage for individual patients, has significantly altered the context of cancer chemotherapy. Precision medicine involves modifying a drug's pharmacological and pharmacokinetic properties without sacrificing the expected outcome at the molecular targets. Specifically, a drug's characteristics for absorption, how it behaves when exposed to both target and non-target cells and how it is administered in synergistic drug mixtures can all be changed.[57] Lipid-based, polymeric, and NPs that are that are created and optimized in growing specific ways can address interdisease and interpersonal differences in biological obstacles against successful DD. In the age of precision healthcare, these engineered and optimized NPs are overcoming the diverse biological barriers present in patients and diseases.[65]

Some of the promising uses of NPs in precision medicine include intracellular targeting, genome engineering, and immunoactivation or suppression.[58]

NANOROBOTS AND NPS

Pharmacytes are self-powered, computer-controlled nanorobotic DDSs that can deliver drugs to specific locations inside the body with extreme precision. Nanorobots can use transmembrane mechanical nanoinjectors to not enter a target cell; they are not always required to be endocytosed.

The use of nanomedicine in the upcoming engineering field of medical nanorobotics will be an exciting advancement in the design, manufacturing, and therapeutic deployment of pharmaceuticals.[59]

CONCLUSION

The modern iteration of Paul Ehrlich's magic bullet idea is nanomedicine. Targeted-delivery nanomedicines can be created using a wide range of NPs. One of the medical sciences' most promising futures for the TDD is the identification and management of fatal illnesses. Due to their superior targeting capabilities, conjugated polymers, polymeric micelles, liposomes in dendrimers, and polymeric NPs are great vehicles for the attachment of drugs and unique structural characteristics. Numerous issues with drug-targeting tactics for clinical use have been found, examined, and resolved, particularly in the management of cancer. Interdisciplinary research, technological advancements, and expertise can all be combined to introduce nanomedicine in a safer manner.

REFERENCES

1. Zishan M, Zeeshan A, Faisal S, Wasim H, Suhail A, Sahar I, *et al.* Vesicular drug delivery system used for liver diseases. World J Pharm Sci 2017;5:28-35.
2. Thakur A, Roy A, Chatterjee S, Chakraborty P, Bhattacharya K, Mahata PP. Recent Trends in Targeted Drug Delivery. Philippines: SM Group. 2015.
3. Kumar A, Nautiyal U, Kaur C, Goel V, Piarchand N. Targeted drug delivery system: Current and novel approach. Int J Pharm Med Res 2017;5:448-54.
4. Akhtar M, Jamshaid M, Zaman M, Mirza AZ. Bilayer tablets: A developing novel drug delivery system. J Drug Deliv Sci Technol 2020;60:102079.
5. Kwon IK, Lee SC, Han B, Park K. Analysis on the current status of targeted drug delivery to tumors. J Control Release 2012;164:108-14.
6. Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers (Basel) 2019;11:640.
7. Ali Y, Alqudah A, Ahmad S, Abd Hamid S, Farooq U. Macromolecules as targeted drugs delivery vehicles: An overview. Des Monomers Polym 2019;22:91-7.
8. Mishra N, Pant P, Porwal A, Jaiswal J, Samad MA, Tiwari S. Targeted drug delivery: A review. Am J Pharm Tech Res 2016;6:20-7.
9. Fahmy TM, Fong PM, Goyal A, Saltzman WM. Targeted for drug delivery. Mater Today 2005;8:18-26.
10. Benyettou F, Motte L. Nanomedicine: Towards the "magic bullet" science. J Bioanal Biomed 2016;8:2.
11. Valent P, Groner B, Schumacher U, Superti-Furga G, Busslinger M, Kralovics R, *et al.* Paul Ehrlich (1854-1915) and his contributions to the foundation and birth of translational medicine. J Innate Immun 2016;8:111-20.
12. Gradmann C. Magic bullets and moving targets: Antibiotic resistance and experimental chemotherapy, 1900-1940. Dynamis 2011;31:305-21.
13. Barz M. Complexity and simplification in the development of nanomedicines. Nanomedicine (Lond) 2015;10:3093-7.
14. Bae YH, Park K. Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 2011;153:198-205.
15. Rani K, Paliwal SA. Review on targeted drug delivery: Its entire focus on advanced therapeutics and diagnostics. Sch J Appl Med Sci 2014;2:328-31.
16. Gujral S, Khatri S. A review on basic concept of drug targeting and drug carrier system. Int J Adv Pharm Biol Chem 2013;2:20-7.
17. Mahajan HS, Patil SB, Gattani SG, Kuchekar BS. Targeted drug delivery systems. Pharma Times 2007;39:20-7.
18. Vyas SP, Khar RK. Targeted and Controlled Drug Delivery: Novel Carrier Systems. New Delhi, India: CBS Publishers and Distributors; 2004.
19. Manish G, Vimukta S. Targeted drug delivery system: A review. Res J Chem Sci 2011;1:135-8.
20. Bhargav E, Madhuri N, Ramesh K, Manne A, Ravi V. Targeted drug delivery - a review. World J Pharm Pharm Sci 2013;3:150-69.
21. Erkoc P, Cinay GE, Kizilel S. Targeted Drug Delivery: Overcoming Barriers through the Design of Novel Delivery Vehicles. Philippines: SM Group; 2015.
22. Jin KT, Lu ZB, Chen JY, Liu YY, Lan HR, Dong HY, *et al.* Recent trends in nanocarrier-based targeted chemotherapy: Selective delivery of anticancer drugs for effective lung, colon, cervical, and breast cancer treatment. J Nanomater 2020;2020:9184284.
23. Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, *et al.* The entry of nanoparticles into solid tumours. Nat Mater 2020;19:566-75.
24. He B, Sui X, Yu B, Wang S, Shen Y, Cong H. Recent advances in drug delivery systems for enhancing drug penetration into tumors. Drug Deliv 2020;27:1474-90.
25. Mills JK, Needham D. Targeted drug delivery. Exp Opin Ther Patents 1999;9:1499-513.
26. Devarajan PV, Jain S, editors. Targeted Drug Delivery: Concepts and Design. New York, Dordrecht, London: Springer Cham Heidelberg; 2015.
27. Bertrand N, Leroux JC. The journey of a drug-carrier in the body: An anatomo-physiological perspective. J Control Release 2012;161:152-63.
28. Öztürk-Atar K, Eroğlu H, Çalış S. Novel advances in targeted drug delivery. J Drug Target 2017;12:199-210.
29. Scott RC, Crabbe D, Krynska B, Ansari R, Kiani MF. Aiming for the heart: Targeted delivery of drugs to diseased cardiac tissue. Expert Opin Drug Deliv 2008;5:459-70.
30. Yu X, Trase I, Ren M, Duval K, Guo X, Chen Z. Design of nanoparticle-based carriers for targeted drug delivery.

J Nanomater 2016;2016:1087250.
31. Idayu IM, Suguna S, Nurul A. Designing polymeric nanoparticles for targeted drug delivery system. Nanomedicine 2015;60:288-311.
32. Bhardwaj A, Kumar L. Colloidal drug delivery systems: A future prospective for treatment of tuberculosis. Am J Pharm Tech Res 2011;1:102-23.
33. Biju S, Talegaonkar S, Mishra P, Khar K. Vesicular systems: An overview. Indian J Pharm Sci 2006;68:141-53.
34. Sunil K, Vipin S, Nancy M, Suman B, Vikas J. Vesicular drug delivery systems: A novel approach for drug targeting. Int J Drug Deliv 2013;5:121-30.
35. Arora S, Lamba HS, Tiwari R. Dermal delivery of drugs using different vesicular carriers. Asian J Pharm 2012;6:237.
36. Priya K, Kumar V, Damini VK, Eswar K, Reddy KR, Raj SB, *et al.* Somes: A review on composition, formulation methods and evaluations of different types of "somes" drug delivery system. Int J Appl Pharm 2020;12:7-18.
37. Anwekar H, Patel S, Singhai AK. Liposome-as drug carrier. Int J Pharm Life Sci 2011;2:945-51.
38. Abu-Dahab R, Schäfer UF, Lehr CM. Lectin-functionalized liposomes for pulmonary drug delivery: Effect of nebulization on stability and bioadhesion. Eur J Pharm Sci 2001;14:37-46.
39. Laouini A, Jaafar-Maalej C, Limayem FH. Preparation, characterization and applications of liposomes: State of the art. J Colloid Sci Biotechnol 2012;1:149-66.
40. Vemuri S, Rhodes CT. Preparation and characterization of liposomes as therapeutic delivery systems: A review. Pharm Acta Helv 1995;70:95-111.
41. Jain RK. Delivery of molecular and cellular medicine to solid tumors. J Colloid Sci Biotechnol 2001;60:2-8.
42. Shukla A. Niosomes: An approach towards targeted drug delivery system. Int J Pharm Pharm Sci 2016;6:40-6.
43. Elsayed MM, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: Reviewing three decades of research. Int J Pharm 2007;332:1-16.
44. Jadhav SM, Morey P, Karpe M, Kadam V. Novel vesicular system: An overview. J Appl Pharm Sci 2012;2:193-202.
45. Gattani YS. Floating multiparticulate drug delivery systems: An overview. Int J Pharm Biol Sci 2010;6:35-40.
46. Kaur R, Kaur S. Role of polymers in drug delivery. J Drug Deliv Ther 2014;4:32-6.
47. Uskokovi D, Stevanovi M. Poly (Lactide- co- glycolide) based micro and nanoparticles for controlled drug delivery of vitamins. Curr Nanosci 2009;5:1-15.
48. Lu K, Wang J, Wang T, Zhong J, Bao Y, Hao H. Recent progress on nanostructures for drug delivery applications. J Nanomater 2016;2016:5762431.
49. Ali Y, Alqudah A, Ahmad S, Abd Hamid S, Farooq U. Macromolecules as targeted drugs delivery vehicles: An overview. Des Monomers Polym 2019;22:91-7.
50. Batrakova EV, Bronich TK, Vetro JA, Kabanov AV. Polymer micelles as drug carriers. In: Torchilin VP, editor. NPs as Drug Carriers. London: Imperial College Press; 2006. p. 57-93.
51. Rav S, Maina SS, Malviya R, Kushwah MG, Khan MG, Yezdani U. Novel approach of targeted drug delivery system and its application. ARC J Public Health Commun Med 2019;4:1-4.
52. Martinho N, Damgé C, Reis CP. Recent advances in drug delivery systems. J Biomater Nanobiotechnol 2011;2:510-26.
53. Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptor-targeted drug delivery: Current perspective and challenges. Ther Deliv 2014;5:1007-24.
54. Rosenblum D, Joshi N, Tao W, Karp JM, Peer D. Progress and challenges towards targeted delivery of cancer therapeutics. Nat Commun 2018;9:1410.
55. Freitas RA Jr. Pharmacytes: An ideal vehicle for targeted drug delivery. J Nanosci Nanotechnol 2006;6:2769-75.
56. Mirza AZ, Siddiqui FA. Nanomedicine and drug delivery: A mini review. Int Nano Lett 2014;4:94.
57. Manzari MT, Shamay Y, Kiguchi H, Rosen N, Scaltriti M, Heller DA. Targeted drug delivery strategies for precision medicines. Nat Rev Mater 2021;6:351-70.
58. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2021;20:101-24.
59. Muro S. Challenges in design and characterization of ligand-targeted drug delivery systems. J Control Release 2012;164:125-37.
60. Telange DR, Pandharinath RR, Pethe AM, Jain SP, Pingale PL. Calcium ion-sodium alginate-piperine-based microspheres: Evidence of enhanced encapsulation efficiency, bio-adhesion, controlled delivery, and oral bioavailability of isoniazid. AAPS PharmSciTech 2022;23:99.
61. Telange DR, Bhaktani NM, Hemke AT, Pethe AM, Agrawal SS, Rarokar NR, *et al.* Development and characterization of pentaerythritol-eudragitrs100 Co-processed excipients as solid dispersion carriers for enhanced aqueous solubility, *in vitro* dissolution, and *ex vivo* permeation of atorvastatin. ACS Omega 2023;8:25195-208.
62. Agrawal SS, Nagendran S, Pimpale A. Advances and prospects in antimicrobial research using nanomedicines. Curr Drug Ther 2023;18:194-204.
63. Rarokar N, Agrawal R, Yadav S, Khedekar P, Ravikumar C, Telange D, *et al*. Pteroyl-γ-l-glutamate/ Pluronic® F68 modified polymeric micelles loaded with docetaxel for targeted delivery and reduced toxicity. J Mol Liquids 2023;369:120842.
64. Dangre PV, Shinde SB, Surana SJ, Jain PG, Chalikwar SS. Development and exploration on flowability of solid self-nanoemulsifying drug delivery system of morin hydrate. Adv Powder Technol 2022;33:103716.
65. Dangre PV, Korekar PP, Borkar MR, Chaturvedi KK, Borikar SP, Pethe AM. Tailoring deep eutectic solvents to provoke solubility and bioavailability of naringin: Implications of a computational approach. ACS Omega 2023;8:12820-9.

Source of Support: Nil. **Conflicts of Interest:** None declared.